What is Chardan Capital’s Estimate for IPSC FY2025 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at Chardan Capital issued their FY2025 EPS estimates for Century Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst Y. Livshits forecasts that the company will earn ($0.33) per share for the year. Chardan Capital currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Chardan Capital also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.64) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The company had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million.

Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Guggenheim cut their price target on shares of Century Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Finally, Piper Sandler decreased their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $5.00.

Century Therapeutics Stock Performance

Shares of IPSC opened at $0.55 on Thursday. Century Therapeutics has a one year low of $0.52 and a one year high of $4.43. The stock has a 50-day moving average price of $0.71 and a 200 day moving average price of $1.13. The company has a market capitalization of $47.19 million, a P/E ratio of -0.30 and a beta of 1.75.

Institutional Investors Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Casdin Capital LLC increased its stake in Century Therapeutics by 61.6% during the fourth quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock valued at $5,242,000 after purchasing an additional 1,978,190 shares during the last quarter. Millennium Management LLC grew its position in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after buying an additional 1,466,415 shares during the last quarter. Renaissance Technologies LLC raised its stake in Century Therapeutics by 146.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock worth $1,215,000 after acquiring an additional 714,685 shares during the period. Geode Capital Management LLC lifted its holdings in Century Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock worth $1,002,000 after acquiring an additional 23,413 shares during the last quarter. Finally, State Street Corp boosted its stake in Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares during the period. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.